[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-prevention":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,67,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100594170","phase-4-kupewa-optimizing-implementation-strategies-for-cervical-cancer-prevention-100594170",false,"NCT07015957","Kupewa: Optimizing Implementation Strategies for Cervical Cancer Prevention","Inclusion Criteria:\n\n* Health workers: People who provide medical care and counseling (typically medical assistants, clinical officers, and nurses), and interact with adolescent girls and young women aged 9-24 and\u002For their parents\u002Fcaregivers.\n* Clients: Non-pregnant females aged 9-24 (for those aged 9-17, their male or female parent\u002Fguardian will also be eligible for participation) who present for HIV care at a participating health facility during the study period.\n\nExclusion Criteria:\n\n* Health workers: Less than 18 years of age, or not an active and regular provider of medical care or counseling at the facility, or unable or unwilling to provide informed consent.\n* Clients: \\\u003C9 or \\>24 years old, or pregnancy, or unable or unwilling to provide informed consent.",true,"ALL","9 Years",{"count":19,"type":20},7000,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is identify an effective and implementable set of implementation strategies to increase cervical cancer prevention in Malawi. The main questions it aims to answer are:\n\n1. Which implementation strategies produce the greatest increase in provider recommendation for, and uptake of, cervical cancer prevention tools among people receiving HIV care.\n2. What is the acceptability, appropriateness, feasibility, and cost of these implementation strategies.\n3. What is the sustained effect of these implementation strategies. The implementation strategies will be conducted with health workers (clinical officers, nurses, and medical assistants): training, coaching, and a reminder system.",[26],"Cervical Cancer Prevention","RECRUITING","2026-04-29",{"date":30,"type":31},"2026-04-30","ACTUAL",{"date":33,"type":31},"2025-07-08",{"date":35,"type":20},"2029-08",{"name":37,"class":38},"New York University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100633745","study-on-the-safety-humoral-immune-response-and-memory-b-cell-response-characteristics-of-sequential-9-valent-hpv-vaccination-100633745","NCT07530679","Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination","A Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential Vaccination With 9-Valent Human Papillomavirus Vaccine (Escherichia Coli) and Bivalent HPV 16\u002F18 Vaccine","Inclusion Criteria:\n\n* 1\\. Female volunteers, aged 18-45 years at the time of receiving the first trial vaccine dose;\n* 2\\. Volunteers (and their legal guardians) are able to understand the study procedures and are capable of complying with protocol requirements (such as collecting biological samples, filling out diary cards, and attending follow-up visits on schedule), and have signed the informed consent form;\n* 3\\. Adult female volunteers agree not to plan a pregnancy and to use effective contraception within 8 months after completing the first dose, or are women who have undergone tubal ligation, subtotal hysterectomy for benign lesions, or removal of benign ovarian tumors;\n\nFor participants in the sequential group, the following additional criteria must be met:\n\n* 4\\. Previously completed the full three-dose schedule of XinKeNing, XiRuiShi, and WoZeHui \\[full three-dose schedule is defined as completing the second and third doses within 12 months after the first dose\\];\n* 5\\. The interval between the last dose of XinKeNing, XiRuiShi, or WoZeHui and the enrollment date is ≥ 12 months.\n\nExclusion Criteria:\n\n* 1\\. Axillary temperature \\> 37.0°C;\n* 2\\. Positive urine pregnancy test in adult female volunteers, or being currently pregnant or breastfeeding;\n* 3\\. Use of any other investigational or unregistered product (drug or vaccine) within 30 days prior to study vaccination, or planned use of other investigational or unregistered products or participation in another clinical study during the study period;\n* 4\\. Long-term (continuous for more than 14 days) use of immunosuppressants or other immunomodulatory medications within 6 months prior to vaccination. Systemic administration of corticosteroid medications is excluded, while topical use (e.g., ointments, eye drops, inhalers, or nasal sprays) is permitted;\n* 5\\. Use of immunoglobulins and\u002For blood products within 3 months prior to vaccination, or planned use within 7 months after the first dose, with the exception of emergency post-exposure use of tetanus immunoglobulin and rabies immunoglobulin;\n* 6\\. Receipt of an inactivated vaccine within 7 days, or a live vaccine within 14 days, prior to study vaccination;\n* 7\\. Experienced fever (axillary temperature ≥38.0°C) within 3 days prior to vaccination, or any serious acute illness requiring systemic antibiotic or antiviral therapy within the past 5 days, or taken medication containing antipyretic ingredients within the past 24 hours;\n* 8\\. Previous vaccination with any HPV vaccine other than Cecolin, Cervarix, or Walvax;\n* 9\\. Suffering from severe immunodeficiency diseases, severe primary diseases of vital organs, cancer (or precancerous lesions), autoimmune diseases (including systemic lupus erythematosus, rheumatoid arthritis, immunodeficiency caused by asplenia or splenectomy due to any reason, and other autoimmune diseases considered by the investigator to potentially affect the immune response);\n* 10\\. History of severe allergies, including severe adverse reactions to previous vaccinations such as anaphylactic shock, acute urticaria, dyspnea, angioedema, or allergy to any component of the study vaccine (aluminum adjuvant, polysorbate, sodium dihydrogen phosphate, disodium hydrogen phosphate);\n* 11\\. Asthma that has been unstable in the past two years, requiring emergency treatment, hospitalization, oral or intravenous corticosteroids;\n* 12\\. Coagulation abnormalities or bleeding disorders;\n* 13\\. Epilepsy, excluding febrile seizures under 2 years of age, alcohol-related seizures in the 3 years prior to abstinence, or simple epilepsy that has not required treatment in the past 3 years;\n* 14\\. Any medical, psychological, social, occupational, or other conditions that, in the judgment of the investigator after reviewing the volunteer's medical history and relevant physical examination, may interfere with the conduct of the clinical study.","FEMALE","18 Years","45 Years",{"count":51,"type":20},360,[53],"NA","This is a single-center, prospective, open-label, partially randomized, matched-controlled trial designed as a cohort study. The study plans to enroll 360 healthy female participants aged 18 to 45 years, divided into three groups: a three-dose sequential group, a two-dose sequential group, and a primary immunization group, with 120 participants in each group. All participants will be stratified by two age subgroups (18-26 years and 27-45 years) to ensure demographic balance across groups.\n\nAs blinding is not feasible in this study, a prospective, open-label, partially randomized, controlled trial design is adopted. A combination of randomized and non-randomized (i.e., partially randomized) enrollment methods is used to balance study feasibility with intergroup comparability.\n\nParticipants in the three-dose sequential group and the primary immunization group will receive one dose of the nine-valent HPV vaccine at months 0, 1, and 6, while those in the two-dose sequential group will receive the nine-valent HPV vaccine at months 0 and 6. Before the second and third doses, investigators must confirm that participants do not meet the criteria for early withdrawal or for postponement of the second and third doses. After each vaccination, a 30-minute safety observation will be conducted at the vaccination site to monitor for adverse events (AEs). Subsequently, the study visit procedures will be followed, including collection of solicited AEs within 7 days post-vaccination, unsolicited AEs within 30 days, and serious AEs (SAEs) throughout the study period. Participants will also complete other scheduled study visits, including safety observations and immunogenicity blood sampling at various time points before and after vaccination.\n\nThe study aims to evaluate the immune response characteristics and safety of sequential vaccination with different doses of the nine-valent HPV vaccine (three doses at 0, 1, 6 months and two doses at 0, 6 months) in healthy female participants who have previously completed vaccination with the bivalent HPV vaccine.",[26],"NOT_YET_RECRUITING","2026-04-08",{"date":59,"type":31},"2026-04-15",{"date":61,"type":20},"2026-04-12",{"date":63,"type":20},"2028-12-31",{"name":65,"class":66},"Jiangsu Province Centers for Disease Control and Prevention","NETWORK",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":39},"100612694","phase-4-a-trial-to-establish-non-inferiority-of-immunogenicity-of-a-single-dose-of-cervavac-quadrivalent-hpv-vaccine-compared-to-the-gardasil-quadrivalent-vaccine-among-girls-and-boys-aged-9-to-14-years-and-in-girlswomen-aged-15-to-20-years-in-zambia-100612694","NCT07256912","A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","CervALONE","Inclusion Criteria:\n\n1. Girl\u002Fwoman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.\n2. Participant willing to sign a written informed consent (for participants 18 years of age and above).\n3. Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).\n4. Participant or parent (s) willing to comply with all study requirements.\n5. Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.\n\nExclusion Criteria:\n\n1. Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.\n2. Participant has a known history of prior vaccination with any HPV vaccine.\n3. Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)\n4. Participant currently enrolled in any other clinical studies of investigational products.\n5. Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.\n6. Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.\n7. Participant has a history of any allergic diseases or severe allergic reaction to any agent\u002Fvaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).\n8. Participant has had an acute illness (moderate or severe) and\u002For fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.\n9. Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.\n10. Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.\n11. Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of \\>0.5 mg\u002Fkg\u002Fday), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.\n12. Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.\n13. Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.\n14. Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.\n15. Participant has history of any cancer, organ transplant or any other immune system disease.\n16. Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures","20 Years",{"count":77,"type":20},1266,[23],"The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls\u002Fwomen aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls\u002Fwomen in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.",[81,82,83,84,26,85],"Vaccine Effectiveness","HPV Vaccination","Single Dose","Immunogenicity","Quadrivalent HPV Vaccine",[87,88,89,90,91],"HPV","VACCINE","SINGLE DOSE","cervical cancer prevention","Quadrivalent HPV vaccine","2026-03-23",{"date":94,"type":31},"2026-03-24",{"date":96,"type":20},"2026-04-01",{"date":98,"type":20},"2029-01-15",{"name":100,"class":38},"International Agency for Research on Cancer",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":15,"sex":47,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":39},"100526638","two-domestic-hpv-vaccines-and-imported-hpv-vaccines-in-women-aged-13-14-years-study-on-immunogenicity-100526638","NCT06137352","Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity","Two Domestic HPV Vaccines (Wozehui ® and Cecolin ®) and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity：A Multi-center Cohort Study in China","Inclusion Criteria:\n\n* Participants who have completed all procedures of domestic bivalent HPV vaccine or imported HPV vaccine and are 30-60 days from the last dose of vaccination at the time of enrollment;\n* The participants are between 13-14 years old at the time of the first dose of domestic or imported HPV vaccination;\n* The participant himself\u002Fherself and his\u002Fher guardian are able to provide proof of legal identity;\n* The participant and his\u002Fher guardian are capable of understanding and signing the informed consent form;\n* Participants are willing to complete study-related follow-up visits and blood collection as required by the protocol.\n\nExclusion Criteria:\n\n* Participants who have received other marketed HPV vaccines, or who have participated in clinical studies of HPV vaccines, or who have participated in clinical studies of other vaccines within the last 6 months;\n* Participants with congenital malformations, developmental disorders, genetic defects, and severe malnutrition that are severe or cause damage to vital organs;\n* Participants with a history of epilepsy, psychosis, and major depression requiring medication, convulsions or seizures or a family history of psychosis;\n* Participants who are immune compromised or have been diagnosed with congenital or acquired immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic Lupus Erythematosus (SLE), Rheumatoid - - Arthritis, Juvenile Rheumatoid Arthritis (JRA), Inflammatory Bowel Disease (IBD), or other autoimmune disease, subjects who have received immunosuppressive therapy within the past 6 months;\n* Absence of spleen, functional absence of spleen, and subjects with any condition resulting in absence of spleen or splenectomy;\n* Subjects with physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders;\n* Participants who, in the judgment of the investigator, have any other factors that make them unsuitable for participation in a clinical trials.","13 Years","14 Years",{"count":111,"type":20},3000,"OBSERVATIONAL","This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women aged 13-14 years. A total of 3,000 subjects who have completed 2 doses of the domestic bivalent HPV vaccine and 3 doses of the imported HPV vaccine will be recruited from Fujian Maternal and Child Health Hospital as the initiator of the study, and will be recruited from a number of healthcare institutions nationwide. Of these, 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Wozehui), 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Cecolin), and 1,000 subjects were vaccinated with the imported HPV vaccine. Each subject was enrolled within 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and a total of two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine. In response to the WHO Cervical Cancer Elimination Strategy, domestic bivalent HPV vaccine has been offered free of charge to adolescent females aged 13-14 years, but there is still a lack of evidence comparing the antibody titer levels of domestic HPV vaccine and imported HPV vaccine in younger females. Therefore, we conducted the present immunogenicity study to explore the immunogenicity and immune persistence after vaccination with domestic bivalent HPV vaccine versus imported HPV vaccine in this age group of females.",[115,116,26],"HPV Infection","HPV Vaccine","2023-11-16",{"date":119,"type":31},"2023-11-18",{"date":121,"type":20},"2023-12-15",{"date":123,"type":20},"2026-12-31",{"name":125,"class":38},"Fujian Maternity and Child Health Hospital"]